Great that you opened a dedicated thread for Oriola as well.
Oriola’s stamp of quality probably stems from the fact that few companies on the Helsinki stock exchange have as strong a market position as Oriola, and the high barrier to entry into the industry acts as a kind of moat. It has over a 40% market share in the wholesale trade of medicines in Finland and Sweden, and that is quite well-cemented. It’s difficult for new players to break into that. The same applies to the company’s pharmacy operations in Sweden, where it has the country’s 3rd largest chain and a network of 327 pharmacies. And at least historically, for example, during 2014-2016, the company has been able to generate quite good profits with these operations.
However, in all these operations, the company has faced many difficulties in recent years, and operating profit has fallen from the 2014-2016 level (around 60 MEUR per year) to the current weak level (around 30 MEUR per year). The company has made many poor choices and really messed up in recent years. One could say that Oriola has the ingredients to be a good company, but these have not been properly utilized in recent years.
The current profit level is weak, and the stock price has rightly followed this dismal development. Finnish wholesale operations have finally been stabilized after the ERP (Enterprise Resource Planning) mess, and operations are becoming more efficient in Mankkaa, which already showed good signs in the Q1 report. However, the Swedish pharmacy market is very tight, and Oriola cannot yet compete with the price competition brought by e-commerce. Operations there should be seriously streamlined to reach previous profitability levels. This, of course, also requires significant investments and marketing efforts for its own online store, which is not cheap either.
The new automated distribution center in Enköping should also improve profitability by the end of 2019, as the company currently has to run both old and new lines simultaneously in Sweden, causing inefficiencies at least in Q2’19. Co-determination negotiations and other efficiency measures should bring 20 MEUR in cost savings by the end of next year. If this were to be fully realized, with everything else remaining constant, the profit could rise back to over 50 MEUR. In that case, I believe the stock’s valuation should be closer to 3 euros than 2 euros.
However, the full realization of the savings can be strongly doubted. In recent years, the company has consistently overestimated its ability to streamline operations while underestimating the speed at which markets/competition have tightened. Oriola’s stock price should be significantly lower than its current level if the profit level remains at the current approximately 30 MEUR. Now, one must trust that management can achieve at least half of the targeted 20 MEUR in savings, which should already lead to a rise in the stock price. Confidence in the company’s guidance and statements has certainly taken quite a hit in recent years, as financial targets have consistently been missed, and solving problems has regularly taken much longer than the company has indicated.
Oriola’s strong market position, established network, customer relationships, product portfolio, etc., are strong assets that the company has not managed to leverage properly. If one invests in the company, one must trust that management can significantly raise profitability above the current level by utilizing these features better than they have been used in recent years. Without profit growth, there will be no better times for the stock price either.